Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium

The planned move into human testing in 2027 remains subject to regulatory clearance.

Rhea-AI Summary

Purple Biotech (PPBT) announced that its IM1240 antibody abstract was selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium.

Amir Horowitz will present in Barcelona on November 20, 2026, at 15:00 CET. The presentation will cover treatment-resistant human tumor models, IM1240's mechanisms of action and NKG2A engagement, plus drug exposure and safety evaluations of CAPTN-3's conditional CD3 masking approach. Purple Biotech plans to complete the work needed to support an application to begin clinical testing and, subject to regulatory clearance, initiate a first-in-human IM1240 study in 2027.

1 point · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.IM1240's first-in-human study is planned for 2027, following completion of work supporting an application for clinical testing.

Negative

• Minor pointIM1240's planned clinical study remains subject to regulatory clearance.

Argus Oct 29 session 10 alerts

+13.86% close to close 1.5x rel. volume Open Argus

Details

Market move: PPBT +13.86% in the Oct 29 session. IM1240 oral presentation

+20.0% Peak in 8 hr 16 min

$1.76M Mkt Cap at Peak Alert

On Oct 29, the day this news came out, PPBT closed 13.86% above the previous close. Argus tracked a peak move of +20.0% during that session. Our momentum scanner recorded 10 alerts for this stock that day. Relative volume reached 1.5x the daily average during tracking.

Data tracked by StockTitan Argus for the Oct 29 session.

Key Figures

Planned first-in-human study: 2027

Planned first-in-human study

2027

IM1240; subject to regulatory clearance

Key Terms

pharmacokinetic, nkg2a engagement, tri-specific antibody, ind-enabling

4 terms

pharmacokinetic medical

"as well as pharmacokinetic and safety evaluation"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

nkg2a engagement medical

"the contribution of NKG2A engagement"

Interaction between the immune receptor NKG2A (found on natural killer cells and some T cells) and its binding partner, typically the HLA‑E molecule on another cell, that transmits an inhibitory signal into the immune cell; when NKG2A is engaged it reduces the activating response of the NK or T cell against the target cell. In therapeutic or research contexts, “NKG2A engagement” can also describe a drug or antibody binding to NKG2A (or to HLA‑E) to mimic, block, or modify that receptor–ligand interaction and thereby change the inhibitory signal.

tri-specific antibody medical

"the lead tri-specific antibody from its CAPTN-3 platform"

A tri-specific antibody is a lab-engineered immune protein designed to bind three different targets at once, such as two disease markers and an immune-cell trigger. Think of it as a three-pronged tool that brings multiple parts of the body’s defense system together or blocks several disease signals simultaneously. Investors care because this approach can produce more potent or versatile treatments with higher potential returns, but it also involves greater scientific complexity, development risk, and regulatory scrutiny.

ind-enabling regulatory

"completing our IND-enabling work"

Ind-enabling describes the preclinical tests and safety work a drug candidate must pass before a company can ask regulators for permission to start human trials (an Investigational New Drug or IND filing). Think of it as the mechanical inspection and crash-testing a prototype car needs before it can legally be driven on public roads; for investors, successful ind-enabling work reduces technical and regulatory risk and makes clinical progress and potential value creation more likely.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Oral presentation: November 20, 2026 at 15:00 CET

REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain, on November 18-20, 2026.

Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented in a plenary session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai.

“We are pleased that our IM1240 abstract has been selected for a plenary session oral presentation at the EORTC-NCI-AACR Symposium,” said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. “We are excited with the progress made in our latest work on the CAPTN-3 platform and its lead candidate IM1240 and we look forward to completing our IND-enabling work and, subject to regulatory clearance, initiating our planned first-in-human clinical study for IM1240 in 2027.”

Presentation:

Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety
Session Title: Plenary Session 7: Proffered Papers
Abstract Number: ENA26-0137
Presenter: Amir Horowitz, Ph.D., Icahn School of Medicine at Mount Sinai
Date and Time: Friday, November 20, 2026, at 15:00 CET

The presentation is planned to be available on the Purple Biotech website following the presentation at the symposium.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers. The platform's lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Purple Biotech plan to begin human testing of IM1240?

Purple Biotech plans to initiate a first-in-human clinical study in 2027, subject to regulatory clearance. The company also plans to complete its IND-enabling work, the studies needed to support an application to begin clinical testing.